Cargando…
Addendum: Perri et al. Electrochemotherapy as a First Line Treatment in Recurrent Squamous Cell Carcinoma of the Oral Cavity and Oropharynx PDL-1 Negative and/or with Evident Contraindication to Immunotherapy: A Randomized Multicenter Controlled Trial. Cancers 2021, 13, 2210
| Autores principales: | , , , , , , , , , , , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
MDPI
2021
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8306106/ http://dx.doi.org/10.3390/cancers13143412 |
| _version_ | 1783727730540412928 |
|---|---|
| author | Perri, Francesco Longo, Francesco Fusco, Roberta D’Alessio, Valeria Aversa, Corrado Pavone, Ettore Pontone, Monica Marciano, Maria Luisa Villano, Salvatore Franco, Pierluigi Togo, Giulia De Fazio, Gianluca Renato Ordano, Daniele Maglitto, Fabio Salzano, Giovanni Maglione, Maria Grazia Guida, Agostino Ionna, Franco |
| author_facet | Perri, Francesco Longo, Francesco Fusco, Roberta D’Alessio, Valeria Aversa, Corrado Pavone, Ettore Pontone, Monica Marciano, Maria Luisa Villano, Salvatore Franco, Pierluigi Togo, Giulia De Fazio, Gianluca Renato Ordano, Daniele Maglitto, Fabio Salzano, Giovanni Maglione, Maria Grazia Guida, Agostino Ionna, Franco |
| author_sort | Perri, Francesco |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-8306106 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2021 |
| publisher | MDPI |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-83061062021-07-25 Addendum: Perri et al. Electrochemotherapy as a First Line Treatment in Recurrent Squamous Cell Carcinoma of the Oral Cavity and Oropharynx PDL-1 Negative and/or with Evident Contraindication to Immunotherapy: A Randomized Multicenter Controlled Trial. Cancers 2021, 13, 2210 Perri, Francesco Longo, Francesco Fusco, Roberta D’Alessio, Valeria Aversa, Corrado Pavone, Ettore Pontone, Monica Marciano, Maria Luisa Villano, Salvatore Franco, Pierluigi Togo, Giulia De Fazio, Gianluca Renato Ordano, Daniele Maglitto, Fabio Salzano, Giovanni Maglione, Maria Grazia Guida, Agostino Ionna, Franco Cancers (Basel) Addendum MDPI 2021-07-08 /pmc/articles/PMC8306106/ http://dx.doi.org/10.3390/cancers13143412 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
| spellingShingle | Addendum Perri, Francesco Longo, Francesco Fusco, Roberta D’Alessio, Valeria Aversa, Corrado Pavone, Ettore Pontone, Monica Marciano, Maria Luisa Villano, Salvatore Franco, Pierluigi Togo, Giulia De Fazio, Gianluca Renato Ordano, Daniele Maglitto, Fabio Salzano, Giovanni Maglione, Maria Grazia Guida, Agostino Ionna, Franco Addendum: Perri et al. Electrochemotherapy as a First Line Treatment in Recurrent Squamous Cell Carcinoma of the Oral Cavity and Oropharynx PDL-1 Negative and/or with Evident Contraindication to Immunotherapy: A Randomized Multicenter Controlled Trial. Cancers 2021, 13, 2210 |
| title | Addendum: Perri et al. Electrochemotherapy as a First Line Treatment in Recurrent Squamous Cell Carcinoma of the Oral Cavity and Oropharynx PDL-1 Negative and/or with Evident Contraindication to Immunotherapy: A Randomized Multicenter Controlled Trial. Cancers 2021, 13, 2210 |
| title_full | Addendum: Perri et al. Electrochemotherapy as a First Line Treatment in Recurrent Squamous Cell Carcinoma of the Oral Cavity and Oropharynx PDL-1 Negative and/or with Evident Contraindication to Immunotherapy: A Randomized Multicenter Controlled Trial. Cancers 2021, 13, 2210 |
| title_fullStr | Addendum: Perri et al. Electrochemotherapy as a First Line Treatment in Recurrent Squamous Cell Carcinoma of the Oral Cavity and Oropharynx PDL-1 Negative and/or with Evident Contraindication to Immunotherapy: A Randomized Multicenter Controlled Trial. Cancers 2021, 13, 2210 |
| title_full_unstemmed | Addendum: Perri et al. Electrochemotherapy as a First Line Treatment in Recurrent Squamous Cell Carcinoma of the Oral Cavity and Oropharynx PDL-1 Negative and/or with Evident Contraindication to Immunotherapy: A Randomized Multicenter Controlled Trial. Cancers 2021, 13, 2210 |
| title_short | Addendum: Perri et al. Electrochemotherapy as a First Line Treatment in Recurrent Squamous Cell Carcinoma of the Oral Cavity and Oropharynx PDL-1 Negative and/or with Evident Contraindication to Immunotherapy: A Randomized Multicenter Controlled Trial. Cancers 2021, 13, 2210 |
| title_sort | addendum: perri et al. electrochemotherapy as a first line treatment in recurrent squamous cell carcinoma of the oral cavity and oropharynx pdl-1 negative and/or with evident contraindication to immunotherapy: a randomized multicenter controlled trial. cancers 2021, 13, 2210 |
| topic | Addendum |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8306106/ http://dx.doi.org/10.3390/cancers13143412 |
| work_keys_str_mv | AT perrifrancesco addendumperrietalelectrochemotherapyasafirstlinetreatmentinrecurrentsquamouscellcarcinomaoftheoralcavityandoropharynxpdl1negativeandorwithevidentcontraindicationtoimmunotherapyarandomizedmulticentercontrolledtrialcancers2021132210 AT longofrancesco addendumperrietalelectrochemotherapyasafirstlinetreatmentinrecurrentsquamouscellcarcinomaoftheoralcavityandoropharynxpdl1negativeandorwithevidentcontraindicationtoimmunotherapyarandomizedmulticentercontrolledtrialcancers2021132210 AT fuscoroberta addendumperrietalelectrochemotherapyasafirstlinetreatmentinrecurrentsquamouscellcarcinomaoftheoralcavityandoropharynxpdl1negativeandorwithevidentcontraindicationtoimmunotherapyarandomizedmulticentercontrolledtrialcancers2021132210 AT dalessiovaleria addendumperrietalelectrochemotherapyasafirstlinetreatmentinrecurrentsquamouscellcarcinomaoftheoralcavityandoropharynxpdl1negativeandorwithevidentcontraindicationtoimmunotherapyarandomizedmulticentercontrolledtrialcancers2021132210 AT aversacorrado addendumperrietalelectrochemotherapyasafirstlinetreatmentinrecurrentsquamouscellcarcinomaoftheoralcavityandoropharynxpdl1negativeandorwithevidentcontraindicationtoimmunotherapyarandomizedmulticentercontrolledtrialcancers2021132210 AT pavoneettore addendumperrietalelectrochemotherapyasafirstlinetreatmentinrecurrentsquamouscellcarcinomaoftheoralcavityandoropharynxpdl1negativeandorwithevidentcontraindicationtoimmunotherapyarandomizedmulticentercontrolledtrialcancers2021132210 AT pontonemonica addendumperrietalelectrochemotherapyasafirstlinetreatmentinrecurrentsquamouscellcarcinomaoftheoralcavityandoropharynxpdl1negativeandorwithevidentcontraindicationtoimmunotherapyarandomizedmulticentercontrolledtrialcancers2021132210 AT marcianomarialuisa addendumperrietalelectrochemotherapyasafirstlinetreatmentinrecurrentsquamouscellcarcinomaoftheoralcavityandoropharynxpdl1negativeandorwithevidentcontraindicationtoimmunotherapyarandomizedmulticentercontrolledtrialcancers2021132210 AT villanosalvatore addendumperrietalelectrochemotherapyasafirstlinetreatmentinrecurrentsquamouscellcarcinomaoftheoralcavityandoropharynxpdl1negativeandorwithevidentcontraindicationtoimmunotherapyarandomizedmulticentercontrolledtrialcancers2021132210 AT francopierluigi addendumperrietalelectrochemotherapyasafirstlinetreatmentinrecurrentsquamouscellcarcinomaoftheoralcavityandoropharynxpdl1negativeandorwithevidentcontraindicationtoimmunotherapyarandomizedmulticentercontrolledtrialcancers2021132210 AT togogiulia addendumperrietalelectrochemotherapyasafirstlinetreatmentinrecurrentsquamouscellcarcinomaoftheoralcavityandoropharynxpdl1negativeandorwithevidentcontraindicationtoimmunotherapyarandomizedmulticentercontrolledtrialcancers2021132210 AT defaziogianlucarenato addendumperrietalelectrochemotherapyasafirstlinetreatmentinrecurrentsquamouscellcarcinomaoftheoralcavityandoropharynxpdl1negativeandorwithevidentcontraindicationtoimmunotherapyarandomizedmulticentercontrolledtrialcancers2021132210 AT ordanodaniele addendumperrietalelectrochemotherapyasafirstlinetreatmentinrecurrentsquamouscellcarcinomaoftheoralcavityandoropharynxpdl1negativeandorwithevidentcontraindicationtoimmunotherapyarandomizedmulticentercontrolledtrialcancers2021132210 AT maglittofabio addendumperrietalelectrochemotherapyasafirstlinetreatmentinrecurrentsquamouscellcarcinomaoftheoralcavityandoropharynxpdl1negativeandorwithevidentcontraindicationtoimmunotherapyarandomizedmulticentercontrolledtrialcancers2021132210 AT salzanogiovanni addendumperrietalelectrochemotherapyasafirstlinetreatmentinrecurrentsquamouscellcarcinomaoftheoralcavityandoropharynxpdl1negativeandorwithevidentcontraindicationtoimmunotherapyarandomizedmulticentercontrolledtrialcancers2021132210 AT maglionemariagrazia addendumperrietalelectrochemotherapyasafirstlinetreatmentinrecurrentsquamouscellcarcinomaoftheoralcavityandoropharynxpdl1negativeandorwithevidentcontraindicationtoimmunotherapyarandomizedmulticentercontrolledtrialcancers2021132210 AT guidaagostino addendumperrietalelectrochemotherapyasafirstlinetreatmentinrecurrentsquamouscellcarcinomaoftheoralcavityandoropharynxpdl1negativeandorwithevidentcontraindicationtoimmunotherapyarandomizedmulticentercontrolledtrialcancers2021132210 AT ionnafranco addendumperrietalelectrochemotherapyasafirstlinetreatmentinrecurrentsquamouscellcarcinomaoftheoralcavityandoropharynxpdl1negativeandorwithevidentcontraindicationtoimmunotherapyarandomizedmulticentercontrolledtrialcancers2021132210 |